LB Pharmaceuticals Inc
Organization details
- Legal name
- LB Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LBRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001691082
Board of directors
-
Heather D. Turner · Director · Chief Executive OfficerSince 2025
-
J. Scott Garland · DirectorSince 2025
-
Ran Nussbaum · DirectorSince 2025
-
Rebecca Luse · DirectorSince 2025
-
Rekha Hemrajani · DirectorSince 2025
-
Robert A. Lenz · DirectorSince 2026
-
Robert R. Ruffolo · DirectorSince 2025
-
William P. Kane Jr. · DirectorSince 2025
-
Zachary Prensky · DirectorSince 2025
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.3%
-
93.4%
Board connections
6 of this board's directors also sit on 10 other boards. 10 are in the same sector.
-
ALX Oncology Holdings Inc. Same sectorvia J. Scott Garland and Rekha Hemrajani
-
Avalyn Pharma Inc. Same sectorvia Heather D. Turner
-
BioAge Labs Inc. Same sectorvia Rekha Hemrajani
-
Elicio Therapeutics Inc. Same sectorvia Robert R. Ruffolo
-
Enliven Therapeutics Inc. Same sectorvia J. Scott Garland
-
Keros Therapeutics Inc. Same sectorvia Ran Nussbaum
-
MaxCyte Inc. Same sectorvia Rekha Hemrajani
-
NovaBridge Biosciences Same sectorvia Robert A. Lenz
-
Olema Pharmaceuticals Inc. Same sectorvia J. Scott Garland
-
UroGen Pharma Ltd. Same sectorvia Ran Nussbaum
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Derivative conversion | +686,138 | — | — |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Derivative conversion | +411,681 | — | — |
| Sep 12, 2025 | Ran Nussbaum Director | Derivative conversion | +411,681 | — | — |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Derivative conversion | +547,648 | — | — |
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Open-market purchase | +2,000,000 | $15.00 | $30,000,000 |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Sep 12, 2025 | Ran Nussbaum Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Derivative conversion | +1,262 | — | — |
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Open-market purchase | +666,666 | $15.00 | $9,999,990 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Open-market purchase | +332,566 | $15.00 | $4,988,490 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Open-market purchase | +767 | $15.00 | $11,505 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about LB Pharmaceuticals Inc
Who is the CEO of LB Pharmaceuticals Inc?
Heather D. Turner has been LB Pharmaceuticals Inc's Chief Executive Officer since September 2025.
How many directors are on LB Pharmaceuticals Inc's board?
LB Pharmaceuticals Inc's board has 9 directors: Heather D. Turner, J. Scott Garland, Ran Nussbaum, Rebecca Luse, Rekha Hemrajani, Robert A. Lenz, Robert R. Ruffolo, William P. Kane Jr. and Zachary Prensky.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="lb-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.